18 January 2015
Life Sciences: Cyclenium Pharma and IRICoR Conclude Collaborative Research Agreement
Cyclenium Pharma, an emerging pharmaceutical company headquartered in Sherbrooke, has just concluded a collaborative research agreement with the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR), affiliated with the Université de Montréal.
Cyclenium Pharma specializes in the discovery and development of new drug candidates using macrocyclic chemical processes. Using its new exclusive CMRTTM technology, it creates innovative small molecule drugs.
The scope of this agreement will make it possible to combine this library of macrocyclic molecules developed by Cyclenium Pharma with the expertise of the Institute for Research in Immunology and Cancer to accelerate the discovery of new pharmaceutical products to treat cancers and other immunological disorders.
Cyclenium Pharma also has a collaborative research agreement with the Southern Research Institute in Alabama.
Sources: Cyclenium Pharma and IRICoRBack to the news